135.80 0.00 (0.00%)
After hours: 4:47PM EDT
|Bid||135.56 x 900|
|Ask||135.64 x 800|
|Day's Range||135.29 - 137.20|
|52 Week Range||99.14 - 137.20|
|Beta (3Y Monthly)||0.82|
|PE Ratio (TTM)||38.15|
|Earnings Date||Aug 6, 2019 - Aug 12, 2019|
|Forward Dividend & Yield||1.36 (1.04%)|
|1y Target Est||146.20|
The healthcare company delivered solid growth in Q4 and beat Wall Street estimates on both the top and bottom lines.
Steris (STE) delivered earnings and revenue surprises of 6.25% and 4.62%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Derby, Britain-based company said it had profit of $1.27. Earnings, adjusted for one-time gains and costs, were $1.53 per share. The results topped Wall Street expectations. The ...
Dublin, Ireland, May 13, 2019 (GLOBE NEWSWIRE) -- - STERIS plc (STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2019 fourth quarter ended March 31, 2019. Revenue as reported for the quarter increased 7% to $768.2 million compared with $716.0 million in the fourth quarter of fiscal 2018, with growth across all segments. Constant currency organic revenue (see Non-GAAP Financial Measures) growth was 9% for the fourth quarter of fiscal 2019.
Continued execution of consumer and medical strategies, launch of new products and strong international footprint are likely to aid Aurora Cannabis (ACB) in Q3.
Steris plc NYSE:STEView full report here! Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is extremely low for STE with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting STE. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $2.15 billion over the last one-month into ETFs that hold STE are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Steris (STE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Anticipated growth across core business unit and solid show by Medical Surgical and European Pharmaceutical Solutions is likely to aid McKesson's (MCK) Q4 earnings. However, rising costs might be a dampener.
Better-than-expected performance at Pharmaceutical and Medical segments and diverse product portfolio is likely to aid Cardinal Health (CAH) in Q3 earnings. However, stiff competition might play spoilsport.
Better-than-expected performance at Kidney Care, strategic buyouts and international expansion might aid DaVita (DVA) in Q1. However, integration risks might be a dampener.
Masimo (MASI) obtains CE mark of the ANI module for the Masimo Root Patient Monitoring and Connectivity Hub, which is likely to strengthen its expanding Root platform.
STERIS plc (STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2019 fourth quarter and full year financial results at 10:00 a.m. Eastern Time on Tuesday, May 14, 2019. The conference call can be heard live over the Internet at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc. A press release detailing fourth quarter and full year 2019 financial results will be issued after the U.S. market closes on May 13, 2019.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! STERIS plc (NYSE:STE) saw a decent share price growth in the teens...
Better-than-expected performance at Pharmaceutical Distribution and World Courier and higher revenues might aid AmerisourceBergen (ABC) in Q2 earnings. However, stiff competition might be a dampener.
Better-than-expected performance at mass cytometry market and higher revenues is likely to aid Fluidigm's (FLDM) in Q1 earnings. However, sluggishness in microfluidics market remains a dampener.
Higher Consumable revenues, product innovation and focus on R&D likely to aid DENTSPLY SIRONA (XRAY) in Q1 earnings. However, contraction is gross margin might be a dampener.
Better-than-expected performance at C&V and Cardiac & Neuromodulation product lines and higher revenues might aid Integer Holdings (ITGR) in Q1. But decline in non-medical sales might be a dampener.
Two important questions to ask before you buy STERIS plc (NYSE:STE) is, how it makes money and how it spends its cash. After investment, what’s left over is what belongs to you, the investor. This also determines how much the stock...
World-class money managers like Ken Griffin and Barry Rosenstein only invest their wealthy clients' money after undertaking a rigorous examination of any potential stock. They are particularly successful in this regard when it comes to small-cap stocks, which their peerless research gives them a big information advantage on when it comes to judging their worth. […]